Glucophage Plus Myo-Inositol vs Glucophage in Glycemic Control Among Patients With Gestational Diabetes Mellitus

NCT ID: NCT06840613

Last Updated: 2025-02-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-31

Study Completion Date

2025-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized controlled trial aims to compare the efficacy of Glucophage plus Myo-Inositol versus Glucophage alone in glycemic control among patients with gestational diabetes mellitus (GDM). The study will assess whether the addition of Myo-Inositol improves glycemic control and reduces insulin requirements in GDM patients. Participants will be randomized into two groups: one receiving Myo-Inositol in combination with Glucophage and the other receiving Glucophage alone. The primary outcome will be glycemic control as assessed by fasting and postprandial glucose levels. Secondary outcomes include insulin requirement and gestational age at initiation of insulin therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This prospective, single-center, randomized controlled trial is designed to evaluate the efficacy of Myo-Inositol supplementation in combination with Glucophage compared to Glucophage alone for glycemic control in women diagnosed with gestational diabetes mellitus (GDM). The trial will be conducted at SIMS/Services Hospital Lahore under the supervision of the University of Health Sciences Lahore.

Gestational diabetes mellitus (GDM) is a condition characterized by glucose intolerance that is first recognized during pregnancy, posing significant health risks for both the mother and fetus. Despite various treatment approaches, achieving optimal glycemic control remains a challenge. While Glucophage (Metformin) is widely used for managing GDM, Myo-Inositol has gained attention for its potential role in improving insulin sensitivity and reducing the need for additional pharmacological interventions.

Study Design and Methodology:

This study will enroll 90 participants aged 18-35 years with singleton pregnancies diagnosed with GDM between 22-32 weeks of gestation.

Participants will be randomly assigned to one of two intervention groups:

Experimental Group (Group A): Patients will receive 2000 mg Myo-Inositol (two capsules) with 500 mg Glucophage, three times a day.

Control Group (Group B): Patients will receive 500 mg Glucophage, three times a day.

All participants will be educated on lifestyle modifications and dietary control, and their blood glucose levels will be monitored throughout the study.

Data will be collected at baseline and at multiple time points during pregnancy to assess glycemic control, the need for insulin therapy, and any adverse effects associated with the interventions.

Rationale for the Study:

Myo-Inositol is an insulin-sensitizing agent that plays a crucial role in glucose metabolism. Emerging evidence suggests that Myo-Inositol supplementation may reduce insulin resistance, lower blood glucose levels, and decrease the likelihood of requiring insulin therapy. By comparing its effects in combination with Glucophage, this study aims to determine whether Myo-Inositol can serve as an effective adjunct therapy for managing GDM.

Expected Outcomes and Implications:

Primary Outcome: Improved glycemic control as measured by fasting and postprandial blood glucose levels.

Secondary Outcomes: Reduction in the number of patients requiring insulin therapy, delayed initiation of insulin if needed, and improved maternal and fetal outcomes.

The results of this study could help shape future clinical guidelines for GDM management, offering a non-invasive, cost-effective alternative to conventional treatment approaches.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gestational Diabetes Mellitus (GDM)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Glucophage Plus Myo-Inositol

Intervention: Patients in this group will receive 2 capsules of Myo-Inositol (2000 mg each) along with 500 mg Glucophage three times a day.

Monitoring: Blood glucose levels will be measured at baseline and after treatment.

Group Type ACTIVE_COMPARATOR

Myo-Inositol

Intervention Type OTHER

Intervention: Patients in this group will receive 2 capsules of Myo-Inositol (2000 mg each) along with 500 mg Glucophage three times a day.

Monitoring: Blood glucose levels will be measured at baseline and after treatment

Glucophage

Intervention Type OTHER

Intervention: Patients in this group will receive 500 mg Glucophage three times a day.

Monitoring: Blood glucose levels will be measured at baseline and after treatment.

Glucophage Alone

Intervention: Patients in this group will receive 500 mg Glucophage three times a day.

Monitoring: Blood glucose levels will be measured at baseline and after treatment.

Group Type ACTIVE_COMPARATOR

Glucophage

Intervention Type OTHER

Intervention: Patients in this group will receive 500 mg Glucophage three times a day.

Monitoring: Blood glucose levels will be measured at baseline and after treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Myo-Inositol

Intervention: Patients in this group will receive 2 capsules of Myo-Inositol (2000 mg each) along with 500 mg Glucophage three times a day.

Monitoring: Blood glucose levels will be measured at baseline and after treatment

Intervention Type OTHER

Glucophage

Intervention: Patients in this group will receive 500 mg Glucophage three times a day.

Monitoring: Blood glucose levels will be measured at baseline and after treatment.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 to 35 years and Singleton pregnancy
* GDM diagnosed during pregnancy as per operational definition
* 22 to 32 weeks of gestation
* No more than 35 days after GDM diagnosis
* BMI of 18 to 29
* Capacity for self-monitoring of blood glucose

Exclusion Criteria

* Patients with obesity BMI more than or equal to 30.
* Already taking insulin during this pregnancy or oral hypoglycemic agents
* Patients taking long time corticosteroid treatment
* Patients with history of pre-existing diabetes
* Overt diabetes diagnosed during pregnancy, i.e. fasting plasma glucose ≥ 126 mg/dL (7 mmol/l) and/or 2-hour post OGTT plasma glucose value ≥ 200 mg/dL (11.1 mmol)
* History of any bariatric surgery
* Twin pregnanc
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Health Sciences Lahore

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hifza Rasheed

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dr. Hifza Rasheed

Role: CONTACT

+923338377083

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Exp129

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Oral Antidiabetic Agents in Pregnancy
NCT02091336 UNKNOWN PHASE4
Hyperemesis Gravidarum Risk Reduction With Metformin
NCT07129473 NOT_YET_RECRUITING PHASE2